Chinese Biotech and US Wound Care: 3 Things Clinicians Should Watch in 2026

If you select wound care biologics for your clinic or hospital system, you already know the product landscape is changing. New amniotic membranes, placental-derived grafts, and peptide-based dressings appear every quarter — and a growing share of them originate from Asia-Pacific manufacturers. Here is what the shift means for clinical decision-making in 2026.

China's biotech manufacturing sector has expanded beyond small-molecule APIs into the biologics and biomaterials that wound care clinicians use every day. The same production infrastructure that scaled GLP-1 manufacturing to global volume — China's peptide API market now accounts for roughly 38% of global value and is growing at over 23% volume CAGR — now produces amniotic membrane products, antimicrobial peptides, and advanced wound dressings at cost structures 30–50% below US-sourced equivalents.

This is not inherently a problem. Lower-cost options can expand access to biologic wound care. But the decision to adopt a product sourced from Asia-Pacific carries clinical, regulatory, and operational dimensions that go beyond the price-per-square-centimeter — and many purchasing decisions are made without full visibility into those differences.

Here are the three factors every wound care clinician should evaluate when comparing US-sourced and APAC-sourced wound care biologics in 2026.

1. Regulatory Pathway: 361 HCT/P Is Not One Standard

Most amniotic membrane and placental-derived wound care products in the US are regulated under FDA 21 CFR Part 1271 — the Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/P) framework. Products meeting all criteria in Section 361 are exempt from premarket approval and regulated solely under tissue establishment registration.

The critical detail: the 361 pathway requires that the tissue be minimally manipulated, intended for homologous use, and not combined with another article. US processors operate under the American Association of Tissue Banks (AATB) accreditation, which mandates donor screening, recovery standards, processing validation, and sterility assurance levels that meet FDA cGMP expectations.

APAC manufacturers exporting to the US must register as tissue establishments with the FDA and designate a US agent. Some do. Some do not. A product that appears "FDA-registered" on paper may have been processed under standards that differ materially from AATB-accredited facilities — in donor screening rigor, processing validation, endotoxin testing frequency, and sterilization dose audit.

2. Cold Chain and Product Consistency

Amniotic membrane allografts are living or decellularized tissues that require strict temperature management from recovery through implantation. Cryopreserved products must remain at -80°C. Dehydrated products must remain below 30°C. A break in either cold chain — an offloaded shipping container, a tarmac delay, a warehouse overnight at room temperature — degrades growth factor content and structural integrity.

APAC-sourced products cross 8,000 to 10,000 miles of ocean freight before reaching a US distribution center. The longer the logistics chain, the more handoffs, the greater the probability of thermal excursion. Published data on international cold chain shipments suggests that 12–18% of temperature-sensitive biologics experience at least one excursion during trans-Pacific transit.

US-sourced biologics from AATB-accredited domestic processors travel from recovery facility to processing to distribution within a contiguous domestic cold chain — typically days rather than weeks, with fewer handoffs and auditable temperature logs at every step. This does not guarantee every domestic product is superior, but the logistics risk profile is structurally different.

3. Clinical Evidence Base: The Preclinical Gap

The strongest US amniotic membrane products have accumulated clinical evidence across multiple wound types — randomized trials in diabetic foot ulcers, prospective registries in venous leg ulcers, retrospective series in pressure injuries, and surgical applications. The evidence spans years and multiple investigator groups.

Many APAC-sourced wound care biologics enter the US market with bioequivalence data showing comparable growth factor profiles or mechanical properties, but without the same depth of clinical outcome data in the populations US clinicians treat — diabetic foot ulcers with neuropathy, venous stasis wounds in patients on anticoagulation, irradiated post-surgical wounds.

A growth factor concentration assay tells you the graft contains what it claims to contain. It does not tell you whether the graft performs equivalently in a 68-year-old patient with a Wagner Grade 2 diabetic foot ulcer and HbA1c of 8.9%. Clinical evidence is the bridge between biochemistry and patient outcome — and that bridge is shorter for many imported products.

Decision Framework for Sourcing Evaluation

The Bottom Line

Price pressure from APAC manufacturing is real, and it will intensify. The global peptide API market is projected to reach $12 billion by 2031, and the same cost dynamics are extending into wound care biologics. Clinicians and hospital systems that evaluate sourcing decisions on cost alone risk unknowingly accepting higher variability in product quality, cold chain integrity, and clinical evidence depth.

The responsible approach is a structured evaluation: request lot-specific temperature logs, verify AATB accreditation and FDA inspection history, and review the clinical evidence base for the specific wound types you treat. Products that pass all three checks — whether US-sourced or imported — deserve a fair seat at the table. Products that cannot produce this documentation do not get to compete on price alone.